嵌合抗原受体
汽车T细胞治疗
免疫学
抗体
B细胞
医学
免疫
抗体疗法
抗原
T细胞
病毒学
免疫系统
单克隆抗体
作者
Carla Simone Walti,Elizabeth M. Krantz,Joyce Maalouf,Jim B. Boonyaratanakornkit,Jacob Keane-Candib,Laurel Joncas-Schronce,Terry Stevens‐Ayers,Sayan Dasgupta,Justin J. Taylor,Alexandre V. Vinaud Hirayama,Merav Bar,Rebecca Gardner,Andrew J. Cowan,Damian J. Green,Michael J. Boeckh,David G. Maloney,Cameron John Turtle,Joshua Aiden Hill
出处
期刊:JCI insight
[American Society for Clinical Investigation]
日期:2021-04-29
卷期号:6 (11)
被引量:100
标识
DOI:10.1172/jci.insight.146743
摘要
BACKGROUNDLittle is known about pathogen-specific humoral immunity after chimeric antigen receptor-modified T (CAR-T) cell therapy for B cell malignancies.METHODSWe conducted a prospective cross-sectional study of CD19-targeted or B cell maturation antigen-targeted (BCMA-targeted) CAR-T cell therapy recipients at least 6 months posttreatment and in remission. We measured pathogen-specific IgG against 12 vaccine-preventable infections and the number of viral and bacterial epitopes to which IgG was detected ("epitope hits") using a serological profiling assay. The primary outcome was the proportion of participants with IgG levels above a threshold correlated with seroprotection for vaccine-preventable infections.RESULTSWe enrolled 65 children and adults a median of 20 months after CD19- (n = 54) or BCMA- (n = 11) CAR-T cell therapy. Among 30 adults without IgG replacement therapy (IGRT) in the prior 16 weeks, 27 (90%) had hypogammaglobulinemia. These individuals had seroprotection to a median of 67% (IQR, 59%-73%) of tested infections. Proportions of participants with seroprotection per pathogen were comparable to population-based studies, but most individuals lacked seroprotection to specific pathogens. Compared with CD19-CAR-T cell recipients, BCMA-CAR-T cell recipients were half as likely to have seroprotection (prevalence ratio, 0.47; 95% CI, 0.18-1.25) and had fewer pathogen-specific epitope hits (mean difference, -90 epitope hits; 95% CI, -157 to -22).CONCLUSIONSeroprotection for vaccine-preventable infections in adult CD19-CAR-T cell recipients was comparable to the general population. BCMA-CAR-T cell recipients had fewer pathogen-specific antibodies. Deficits in both groups support the need for vaccine and immunoglobulin replacement therapy studies.FUNDINGSwiss National Science Foundation (Early Postdoc Mobility grant P2BSP3_188162), NIH/National Cancer Institute (NIH/NCI) (U01CA247548 and P01CA018029), NIH/NCI Cancer Center Support Grants (P30CA0087-48 and P30CA015704-44), American Society for Transplantation and Cellular Therapy, and Juno Therapeutics/BMS.
科研通智能强力驱动
Strongly Powered by AbleSci AI